UNICREDIT BANK/CALL/VERTEX PHARMACEUTICALS/450/0.1/15.01.25 | Market Closed - BOERSE MUENCHEN 15:42:23 2024-06-07 EDT | ||
| 6.54 EUR | +1.40% |
|
| Current month | +38.85% | ||
| 1 month | +141.33% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-06-07 | 6.54 | +1.40% |
| 24-06-06 | 6.45 | -0.31% |
| 24-06-05 | 6.47 | +9.85% |
| 24-06-04 | 5.89 | +10.51% |
| 24-06-03 | 5.33 | +13.16% |
Real-time BOERSE MUENCHEN
Last update June 07, 2024 at 03:42 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
UniCredit
|
| WKN | HC49Q1 |
| ISIN | DE000HC49Q12 |
| Date issued | 2023-02-20 |
| Strike | 450 $ |
| Maturity | 2025-01-15 (220 Days) |
| Parity | 10 : 1 |
| Emission price | 1.76 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.55 € |
|---|---|
| Lowest since issue | 1.36 € |
| Spread | 0.04 € |
| Spread % | 0.62% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
483
USD
Average target price
463.5
USD
Spread / Average Target
-4.04%
- Stock Market
- Warrants
- Warrant
